Inhibitor Therapeutics (INTI) Prepaid Assets (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Prepaid Assets came in at $84975.0 in Q1 2026, down 14.26% YoY from $99105.0 in Q1 2025, and up 18.83% on a QoQ basis from $71507.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Prepaid Assets (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Prepaid Assets data on file, last reported at $84975.0 in Q1 2026.
- Quarterly Prepaid Assets fell 14.26% year-over-year to $84975.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84975.0 (down 14.26% YoY) and the FY2025 annual result came in at $71507.0, down 18.55% from the prior year.
- Prepaid Assets improved to $84975.0 in Q1 2026, from $71507.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $112399.0 in Q1 2024 to a low of $10059.0 in Q3 2022.
- A 5-year average of $67341.3 and a median of $73138.0 in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets slumped 72.66% — and 2023, when it jumped 596.6%.
- Tracing INTI's Prepaid Assets over 5 years: stood at $23900.0 in 2022, then soared by 357.08% to $109243.0 in 2023, then dropped by 19.63% to $87795.0 in 2024, then declined by 18.55% to $71507.0 in 2025, then gained by 18.83% to $84975.0 in 2026.
- The last three Prepaid Assets figures came in at $84975.0 (Q1 2026), $71507.0 (Q4 2025), and $87428.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84,975.00 |
| Dec 31, 2025 | 71,507.00 |
| Sep 30, 2025 | 87,428.00 |
| Jun 30, 2025 | 92,025.00 |
| Mar 31, 2025 | 99,105.00 |
| Dec 31, 2024 | 87,795.00 |
| Sep 30, 2024 | 73,138.00 |
| Jun 30, 2024 | 74,625.00 |
| Mar 31, 2024 | 112,399.00 |
| Dec 31, 2023 | 109,243.00 |
| Sep 30, 2023 | 70,071.00 |
| Jun 30, 2023 | 58,007.00 |
| Mar 31, 2023 | 52,248.00 |
| Dec 31, 2022 | 23,900.00 |
| Sep 30, 2022 | 10,059.00 |
| Jun 30, 2022 | 13,572.00 |
| Mar 31, 2022 | 24,705.00 |
| Dec 31, 2021 | 28,158.00 |
| Sep 30, 2021 | 36,792.00 |
| Jun 30, 2021 | 33,042.00 |